Screen and identify potentially thousands of hit monoclonal antibodies using up to 80,000 NanoPen chambers per workflow.
Next generation sequencing for barcoded BCR sequences facilitates quick, high-throughput sequence recovery.
Bioinformatics determine sequence diversity and developability. Once threshold plasma titers are reached, hit sequences are returned in just six to twenty days!
Save time and money with an end-to-end workflow that quickly identifies relevant antibodies and provides a seamless path to developing humanized antibodies – in a six-month timeframe or less.
In addition to deploying the Beacon system to identify and select cells of interest, Curia accelerates “First-to-Human” workflows with everything you need to successfully bring a new drug to market, including:
Quick Curia boilerplate. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec tincidunt tellus eget est pretium, gravida iaculis orci euismod.
Fusce vitae ullamcorper dui. Pellentesque tincidunt eros auctor purus porta vestibulum consequat id mi. Mauris ac feugiat elit, ut placerat augue. Sed sit amet sagittis justo, quis lobortis orci.